Open AccessCombining CDK4/6 inhibitors ribociclib and palbociclib with cytotoxic agents does not enhance cytotoxicity
Author(s) -
Dayong Jin,
Nguyen H. Tran,
Nagheme Thomas,
David Tran
Publication year - 2019
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0223555
Subject(s) - palbociclib , cytotoxicity , cytotoxic t cell , cell cycle , cell cycle checkpoint , pharmacology , kinase , cyclin dependent kinase 6 , cancer research , cyclin dependent kinase , retinoblastoma protein , biology , cancer , medicine , breast cancer , microbiology and biotechnology , in vitro , biochemistry , metastatic breast cancer
Cyclin-dependent kinases 4 and 6 (CDK4/6) play critical roles in the G 1 to S checkpoint of the cell cycle and have been shown to be overactive in several human cancers. Small-molecule inhibitors of CDK4/6 have demonstrated significant efficacy against many solid tumors. Since CDK4/6 inhibition is thought to induce cell cycle arrest at the G1/S checkpoint, much interest has been focused on combining CDK4/6 inhibitors with cytotoxic agents active against the S or M phase of the cell cycle to enhance therapeutic efficacy. However, it remains unclear how best to combine these two classes of drugs to avoid their potentially antagonistic effects. Here, we test various combinations of highly selective and potent CDK4/6 inhibitors with commonly used cytotoxic drugs in several cancer cell lines derived from lung, breast and brain cancers, for their cell-killing effects as compared to monotherapy. All combinations, either concurrent or sequential, failed to enhance cell-killing effects. Importantly, in certain schedules, especially pre-treatment with a CDK4/6 inhibitor, combining these drugs resulted in reduced cytotoxicity of cytotoxic agents. These findings urge cautions when combining these two classes of agents in clinical settings.